X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-29-2023-93363.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-7-2022-68481.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-july-6-2022-1657105109.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-01-2022-1654158193.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206497
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-10-2021-1615353629.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210924
https://www.raps.org/news-and-articles/news-articles/2019/9/fda-consults-on-abuse-deterrent-cns-stimulants
https://in.reuters.com/article/us-health-medicines-who/who-keeps-key-lung-cancer-drugs-off-its-essential-medicines-list-idINKCN1U40YS
https://www.raps.org/news-and-articles/news-articles/2019/5/fda-drafts-guidance-for-developing-drugs-to-treat
https://pharmaphorum.com/news/teva-and-neos-settle-over-cotempla-patent-dispute/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210924
https://www.rdmag.com/news/2018/08/ironshore-pharmaceuticals-receives-fda-approval-jornay-pm-treatment-adhd
https://www.thepharmaletter.com/in-brief/brief-ftc-imposes-conditions-on-amneal-acquisition-of-impax
https://www.ftc.gov/news-events/press-releases/2018/07/ftc-approves-final-order-imposing-conditions-merger-generic-drug
https://www.prnewswire.com/news-releases/ani-pharmaceuticals-completes-acquisition-of-generic-products-and-assets-from-amnealimpax-300642867.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-25-2018-1524633895.pdf
https://seekingalpha.com/article/4137615-update-neos-therapeutics-seems-capitalizing-pfizers-decisions
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-cotempla-xr-odt-methylphenidate-extended-release-orally-disintegrating-tablets-1511849518.pdf
https://www.pharmacompass.com/pdf/news/pharmascience-inc-recalls-pms-methylphenidate-er-1508472162.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-september-27-2017-1506575777.pdf
http://lannett.investorroom.com/2017-02-22-Lannett-Provides-Further-Update-On-Methylphenidate-ER-Tablets
https://globenewswire.com/news-release/2016/11/17/890931/0/en/Neos-Therapeutics-Submits-NDA-for-Amphetamine-Extended-Release-Liquid-Suspension-Drug-Candidate-NT-0201-for-the-Treatment-of-ADHD.html
http://www.pharma-excipients.ch/2016/02/05/drug-excipient-interaction-ofmethylphenidate-with-glycerin-inmethylphenidate-oral-solution-andidentification-of-its-transesterificationproducts-by-uplc-ms-ms/
http://www.telegraph.co.uk/women/11859044/Does-your-child-really-need-Ritalin.html
http://www.fiercepharma.com/story/fda-balks-generic-concerta-mallinckrodt-actavis-meds-gobble-market/2015-06-17
http://www.in-pharmatechnologist.com/Ingredients/Johnson-Matthey-Ageing-population-and-generics-will-drive-API-biz-Alfa-Aesar-sale-on-track
http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2015/05/another-punt-return-resolving-180-day-exclusivity-this-time-a-true-post-mma-case-made-in-the-context.html
http://www.fiercebiotech.com/story/collegium-swings-75m-ipo-its-abuse-proof-painkiller/2015-05-01
http://www.thestar.com/news/canada/2015/03/30/health-canada-issues-stronger-clearer-warnings-about-suicide-risks-linked-to-adhd-drugs.html
http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2015/52759a-eng.php
Market Place
Share 
